Callio Therapeutics Advances CLIO-8221 Phase 1 Trial for HER2 Tumors
SEATTLE and SINGAPORE, May 27, 2026 Callio Therapeutics has announced the presentation of its Phase 1 clinical trial design...
MASH
Advertisement
Roche Launches AI-Powered Liver Disease Panel for Early Detection
BASEL, Switzerland, May 27, 2026 Roche has announced the launch of its groundbreaking Liver Disease Panel, the healthcare industry’s...
MetaVia Highlights Vanoglipel’s MASH Fibrosis Potential
CAMBRIDGE, Mass., May 20, 2026 MetaVia Inc. has announced the publication of new peer-reviewed preclinical research supporting the anti-fibrotic...
Innovent Highlights Obesity Pipeline at ADA 2026
SAN FRANCISCO and SUZHOU, China, May 12, 2026 Innovent Biologics announced that it will present multiple clinical and preclinical...
Arrowhead Pharmaceuticals and Madrigal Announce MASH Deal
PASADENA, Calif., United States – May 5, 2026 Arrowhead Pharmaceuticals Inc. has entered into an exclusive global licensing agreement...
Advertisements
Boehringer Survodutide Shows 16.6% Weight Loss in Phase III
INGELHEIM, GERMANY, April 28, 2026 Boehringer Ingelheim has announced positive Phase III results for its investigational dual agonist survodutide,...
Sagimet Advances MASH Combination Therapy With Phase 1 PK Data
SAN MATEO, Calif., Dec. 18, 2025 — Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on metabolic and fibrotic...
Morphocell Secures $50M to Advance Stem-Cell Liver Therapy
Laval, Québec, December 1, 2025 — Morphocell Technologies has announced the successful completion of its US$50 million Series A...
Can-Fite Highlights Major Progress Across Late-Stage Drug Pipeline
Ramat Gan, Israel, November 26, 2025 — Can-Fite BioPharma has announced key updates across its advanced-stage clinical pipeline ahead...
Tangram Advances TGM-312 With Phase 1/2 CTA Submission
LONDON — November 26, 2025. Tangram Therapeutics has submitted a Clinical Trial Application (CTA) to the UK Medicines and...
Advertisement
